Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.98 +1.28%

+$0.16 today

Market cap
$150.57M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.23M

Average 0.35M

Balance Sheet

Inspect the capital base behind the business.

Assets

$278.35M

FY 2025 · Annual

Liabilities

$71.07M

FY 2025 · Annual

Equity

$207.29M

FY 2025 · Annual

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$267.8M
Receivables$15.0M
Other Current$2.7M
Total Current Assets$285.6M
PP&E (Net)$6.4M
Long-term Investments$415.0K
Total Non-current Assets$6.8M
Total Assets$292.4M

Analysis

Selected assets total $292.4M for Latest. The largest visible component is Cash & Equivalents at $267.8M, about 91.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 2, 2026
8-KCurrent reportOct 27, 2026
8-K/A8-K/A filingOct 9, 2026

How much cash does RNA have?

Atrium Therapeutics, Inc. (RNA) reported $270.00M in cash and equivalents in fiscal 2025.

How much debt does RNA carry?

Atrium Therapeutics, Inc. (RNA) reported $3.67M of total debt, with net debt of -$266.33M.